<DOC>
	<DOCNO>NCT00259740</DOCNO>
	<brief_summary>The purpose study determine denosumab effective treatment relapse plateau-phase multiple myeloma .</brief_summary>
	<brief_title>Open-Label , Phase 2 , Proof Concept Study Multiple Myeloma - Denosumab</brief_title>
	<detailed_description>Patients relapse myeloma fail treatment regimen disease progression follow last treatment regimen . Despite new salvage therapy , treatment option limit may include best supportive care investigational therapy . Patients plateau-phase myeloma stabilize serum M-protein level without tumor regression despite continued treatment . Recent evidence suggest prognosis might improve reduction serum M-protein prolongation time disease progression ( TTP ) . These patient candidate investigational agent could reduce tumor burden increase TTP .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>age â‰¥ 18 year clinical diagnosis relapse plateauphase multiple myeloma measurable disease ( &gt; 0.5 g/dL ) determine special blood test ECOG 0 1 newly diagnose myeloma nonsecretory myeloma plasma cell leukemia plasma cell dyscrasia POEMS syndrome prior allogeneic stem cell transplant administration oral IV bisphosphonates within 2 week enrollment study Other criterion also apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Myeloma , Relapsed , Plateau-Phase</keyword>
</DOC>